22nd Century Group Stock News

XXII earnings call for the period ending December 31, 2021.

XXII earnings call for the period ending December 31, 2021.

22nd Century Group (XXII) CEO Jim Mish on Q4 2021 Results - Earnings Call Transcript

22nd Century (XXII) delivered earnings and revenue surprises of -20% and 9.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

22nd Century press release (XXII): Q4 GAAP EPS of -$0.09.Revenue of $8M (+9.6% Y/Y).The company ended the year with a cash position of $48.7 million as of December 31, 2021, and…

BUFFALO, N.Y., March 01, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today reported results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent business highlights. The Company will host a live audio webcast today at 10:00 a.m. ET.

22nd Century (XXII) delivered earnings and revenue surprises of -20% and 9.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

22nd Century Group (XXII) said South Korea will be the first international market to begin sales of its VLN reduced nicotine content cigarettes.First VLN sale is expected by March-end.

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we mak

First revenue from shipment to in-market partner expected by end of March 2022 First revenue from shipment to in-market partner expected by end of March 2022

22nd Century Group, Inc. (NASDAQ: XXII ) an agricultural biotechnology company focused on tobacco harm reduction, congratulated Dr. Robert Califf on his confirmation as FDA Commissioner of the Food and Drug Administration (FDA) . Califf is known to be a longtime proponent of innovative tobacco control programs and a strong supporter of the agency’s comprehensive plan for tobacco and nicotine regulation. “ Cigarette smoking kills nearly half a million Americans every year. With Dr. Califf’s background, we are confident he will use the power the FDA was given by the 2009 tobacco control act to protect and improve public health by introducing regulations that will help smokers break their addiction to cigarettes,” stated James A. Mish , chief executive officer of 22nd Century Group. “The FDA … Full story available on Benzinga.com

FDA’s Rulemaking Process Could Make VLN ® Menthol King Reduced Nicotine Cigarettes the Only Menthol Cigarette on the Market

22nd Century Group, Inc. (NASDAQ: XXII ), and its global plant research partner KeyGene achieved a breakthrough in their research leading to the successful transformation of the hemp/cannabis plant genome using proprietary plant transformation, regeneration technology and clear protein expression by the introduced genes. "I cannot emphasize enough what an enormous achievement it is for our company to have cracked the code to show proof of genome transformation in the hemp/cannabis plant. This is the holy grail in plant science and places us in a commanding leadership position in the Full story available on Benzinga.com

Turning Point Brands (TPB) delivered earnings and revenue surprises of 46.67% and 5.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?